Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

August 28, 2026

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

August 27, 2026

Asieris Pharmaceuticals’ Portable Blue Light Flexible Cystoscope APLD-2304 Receives EU CE Mark

August 26, 2026

Asieris Received NMPA IND Approval for CLDN6/9-ADC for the Treatment of Advanced Solid Tumors

August 13, 2026

Asieris Received FDA IND Approval for CLDN6/9- ADC for the Treatment of Advanced Solid Tumors

Asieris Pharmaceuticals and Obstetrics & Gynecology Hospital of Fudan University Sign Strategic Cooperation Agreement

World Reproductive Health Day: World’s First Non-Invasive Portable Cervical Photodynamic Therapy Technology Launched Across 26 Cities in China, Offering a Fertility-Preserving Treatment Option for Patients with Cervical Precancer

Technology Platform